泰它西普治疗原发性干燥综合征的疗效与安全性:一项随机、双盲、安慰剂对照的2期试验
这项2期随机双盲安慰剂对照试验纳入42例抗SSA抗体阳性且ESSDAI≥5的成人原发性干燥综合征患者,按1:1:1随机接受每周皮下注射泰它西普240 mg、160 mg或安慰剂24周。泰它西普160 mg组第24周ESSDAI较基线下降显著优于安慰剂(安慰剂校正的最小二乘均值变化为-4.3,95%CI -7.0至-1.6,P=0.002);240 mg组ESSDAI平均变化为-2.7(-5.6至0.1),与安慰剂组相比无统计学差异(P=0.056)。两个泰它西普组第24周MFI-20和血清免疫球蛋白均较安慰剂显著下降(P<0.05),泰它西普治疗组未观察到严重不良事件。
要点
- 泰它西普160 mg组第24周ESSDAI较基线下降显著优于安慰剂,安慰剂校正的最小二乘均值变化为-4.3(95%CI -7.0至-1.6,P=0.002)。
- 泰它西普240 mg组ESSDAI平均变化为-2.7(-5.6至0.1),与安慰剂组相比无统计学差异(P=0.056)。
- 两个泰它西普组第24周MFI-20和血清免疫球蛋白均较安慰剂显著下降(P<0.05),泰它西普治疗组未观察到严重不良事件。
核心结论
- 泰它西普在原发性干燥综合征治疗中显示出临床获益,且耐受性和安全性良好。
研究设计与样本
- 2期随机、双盲、安慰剂对照试验,纳入抗SSA抗体阳性且ESSDAI≥5的成人原发性干燥综合征患者。
- 患者按1:1:1比例随机接受每周皮下注射泰它西普240 mg、160 mg或安慰剂,疗程24周。
- 共入组并随机化42例患者,每组14例。
- 主要终点为第24周ESSDAI较基线的变化。
- 试验注册号:ClinicalTrials.gov NCT04078386。
主要发现
- 泰它西普160 mg组第24周ESSDAI较基线显著下降,与安慰剂组相比差异有统计学意义(P<0.05),安慰剂校正的最小二乘均值变化为-4.3(95%CI -7.0至-1.6,P=0.002)。
- 泰它西普240 mg组ESSDAI平均变化为-2.7(-5.6至0.1),与安慰剂组相比无统计学差异(P=0.056)。
- 两个泰它西普组第24周MFI-20和血清免疫球蛋白均较安慰剂组显著下降(P<0.05)。
- 泰它西普治疗组未观察到严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of telitacicept in adult patients with primary SS (pSS) in a phase II randomized double-blind placebo-controlled trial. METHODS: Patients with pSS with positive anti-SSA antibody and ESSDAI ≥ 5 were randomly assigned, in a 1:1:1 ratio, to receive weekly subcutaneous telitacicept 240 mg, 160 mg, or placebo for 24 weeks. The primary end point was the change from baseline in the ESSDAI at week 24. Safety was monitored. RESULTS: A total of 42 patients were enrolled and randomized (n = 14 per group). Administration of telitacicept 160 mg resulted in a significant reduction in ESSDAI score from baseline to week 24 compared with placebo (P < 0.05). The placebo-adjusted least-squares mean change from baseline was -4.3 (95% CI -7.0, -1.6; P = 0.002). While, mean change of ESSDAI in telitacicept 240 mg was -2.7(-5.6-0.1) with no statistical difference when compared that in placebo group (P = 0.056). In addition, MFI-20 and serum immunoglobulins decreased significantly (P < 0.05) at week 24 in both telitacicept groups compared with placebo. No serious adverse events were observed in the telitacicept treating group. CONCLUSION: Telitacicept showed clinical benefits and good tolerance and safety in the treatment of pSS. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04078386.
引用
- Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2024. PMID: 37399108. doi:10.1093/rheumatology/kead265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。